Clinical Trial Update: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of ladiratuzumab vedotin in multiple advanced solid tumors was terminated, with results posted in March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Ladiratuzumab Vedotin (ladiratuzumab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous | Phase 2 | Status: TERMINATED | Results posted: 2025-03-10